Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 26th June 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer's classical swine fever live vaccine approved
CSF has caused huge economic losses to China's pig farming industry.
Vaccine will play a vital role in eradicating the disease in China.

The first classical swine fever (CSF) live vaccine, jointly developed by Boehringer Ingelheim and Chinese research institutes, has received marketing approval.

The newly-approved Ingelvac CSF MLV is set to provide China's swine industry with breakthrough immunization programmes and support disease solutions. It will also play a vital role in eradicating CSF in the country.

CSF is a highly contagious, lethal disease that has caused huge economic losses to China's pig farming industry. While the outbreak is now effectively controlled by mass vaccination with CSF live vaccine, endemic and sporadic spread remains.

Existing CSF live vaccines can only be stored at -15℃  for 18 months, with strict temperature control requires for transportation, storage and dilution. The new vaccine uses state-of-the-art suspension culture and freeze-drying technologies to ensure stable vaccine production process, and controllable quality. It can be stored at 2-8℃ for 24 months.

In a press release, a Boehringer spokesperson said the vaccine ' marks another milestone for Boehringer Ingelheim’s “in China, for China”, as the company is committed to providing innovative and high-quality swine vaccines for the Chinese swine industry, as well as holistic swine disease solutions to pig farms.'

Ingelvac® CSF MLV will be produced by Boehringer Ingelheim’s Taizhou plant and is expected to be commercialised in early 2021. 

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
RCVS members invited to question Council candidates

RCVS members have been invited to submit questions to candidates for this year's RCVS Council election.

With 15 candidates standing for three available positions, vets have been invited to submit a question of their choosing before voting starts. These questions will be collated, with each candidate answering one question of their choice.

It is recommended that members read the candidates' biographies and statements before submitting questions. One question per member can be submitted to vetvote26@rcvs.org.uk before Wednesday, 25 February 2026.

The RCVS Council election is due to start in March.

With only two candidates for two positions on the VN Council, there will be no VN Council elections this year. Meghan Conroy RVN and Lauren Hargrave RVN will begin their three year terms at RCVS' AGM in July.